Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context.
UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today (September 29) with disease model, ioGlutamatergic Neurons TDP-43 and early access to its ioMicroaglia cell product.
Despite research efforts and funding, bit.bio says the development of therapies for devastating diseases like Alzheimer’s disease (AD), Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) has been challenging.
Scientists have had to rely on animal models and cell lines that are considerably different to human biology, which bit.bio says is due to a lack of standardized, easy to use, readily accessible human cell models.
With consistency across batches and a scalable supply, bit.bio’s products will significantly reduce experimental variability in non-clinical studies and improve the translatability and reproducibility of research findings. The company says the product features have the potential to transform research and drug discovery.
Dr Mark Kotter, CEO and founder of bit.bio said: “This is another step towards our vision of an exciting future in which precision reprogrammed human cells will accelerate biomedical innovation and a new generation of cures. The launch of two new cell products for research and drug discovery in neurodegenerative diseases validates our cell identity coding platform’s ability to create and manufacture any human cell type consistently at scale.”
“The products we are announcing today address an area of high unmet clinical need where high failure rates in drug development are common and no effective treatments exist. I look forward to seeing how our customers will use them to develop new insights and treatments for these devastating conditions.”
No treatment options
bit.bio says AD and FTD, the leading causes of early onset dementia, have no treatment options to stop or slow their onset. Similarly, current treatment options for ALS, the most common motor neuron degenerative disease, are limited.
ioGlutamatergic Neurons TDP-43M337V, have a mutation in the TAR DNA binding protein gene that codes for the TDP-43 protein, which is known to cause both FTD and ALS. The disease model cells and the genetically matched control, ioGlutamatergic Neurons, mature rapidly, are highly reproducible between batches, and have unprecedented scalability.
These key features make them ideally suited to high-throughput screening applications for early drug discovery. Being able to compare data from the physiologically-relevant disease models to those of the control offers the potential to identify and investigate the effects of the genetic mutation on the disease mechanisms of FTD and ALS.
bit.bio’s products address major challenges
bit.bio says that increasing evidence suggests that microglia contribute to the onset and progression of AD and are involved in the pathogenesis of ALS and FTD. Therefore they may represent an additional therapeutic target. However, speed, variability, and scalability continue to be major challenges with commonly used microglia. ioMicroglia, now available as part of an early access program, address these challenges allowing scientists to work with consistent, functional cells that are ready for experimentation within just 10 days.
Farah Patell-Socha, VP research products at bit.bio, said: “Human cells are key to disease research, drug discovery, and clinical translation. However, traditional methods of producing human cells have long, laborious, protocols that often result in heterogenous cell populations and can lead to data variability.
“Our latest products provide robust, standardized tools for neurodegenerative research and drug discovery, paving the way for high-throughput screening and drug target validation in human iPSC-derived models that was previously impossible, and bringing huge benefits to medicine as a result.”